Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Antibiotic Resistance Helicobacter Pylori and Clarithromycin Resistance Mutation in Helicobacter Pylori in Rajavithi Hospital
1 other identifier
observational
200
1 country
1
Brief Summary
Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide. The gold standard for Helicobacter pylori eradication is composed of Proton-pump inhibitor/Ranitidine bismuth citrate + Amoxycillin + Metronidazole /Clarithromycin. In Thailand, clarithromycin resistant strains increased and led to treatment failure. Data on file at Rajavithi Hospital showed that metronidazole resistant H. pylori was about 50% and Clarithromycin resistant strains accounted for 8%. This molecular genetic study will be performed in patients presenting with dyspepsia, who had an indication for gastroscopic examination, to explore the incidence of antibiotic resistant Helicobacter pylori in Rajavithi Hospital, Thailand.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 1, 2006
CompletedFirst Posted
Study publicly available on registry
February 2, 2006
CompletedStudy Start
First participant enrolled
June 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2007
CompletedOctober 19, 2020
October 1, 2020
1.5 years
February 1, 2006
October 14, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of H. pylori Clarithromycin resistance gene
one year
Secondary Outcomes (1)
Characteristic of H. pylori clarithromycin resistant gene mutation
one year
Study Arms (2)
1
Gastroscope positive for H. pylori and resistant to clarithromycin
2
Gastroscope positive for H. pylori and not resistant to clarithromycin
Interventions
gastroscopic examination for tissue biopsy and real time PCR for gene study
Eligibility Criteria
Dydpepsia patient with gastroscopic examination
You may qualify if:
- male or female with dyspepsia
- age \> 15 years
- fulfil indication for gastroscopic examination
- able to give informed consent
You may not qualify if:
- contraindication for gastroscopic examination and biopsy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rajavithi Hospital
Ratchathewi, Bangkok, 10400, Thailand
Related Publications (1)
Hansomburana P, Anantapanpong S, Sirinthornpunya S, Chuengyong K, Rojborwonwittaya J. Prevalence of single nucleotide mutation in clarithromycin resistant gene of Helicobacter pylori: a 32-months prospective study by using hybridization real time polymerase chain reaction. J Med Assoc Thai. 2012 Mar;95 Suppl 3:S28-35.
PMID: 22619884DERIVED
Biospecimen
Gastric Biopsy tissue and H. pylori DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Piyathida Harnsoomboon, MD
Department of Medical Services Ministry of Public Health of Thailand
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
February 1, 2006
First Posted
February 2, 2006
Study Start
June 1, 2006
Primary Completion
December 1, 2007
Study Completion
December 1, 2007
Last Updated
October 19, 2020
Record last verified: 2020-10